Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research

References

• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223–238. doi:10.1038/s41575-020-00381-6
   PubMed Web of Science ®Google Scholar
• Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. Dig Dis Sci. 2016;61:1325–1336. doi:10.1007/s10620-015-3977-1
   PubMed Web of Science ®Google Scholar
• Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2018;68:230–237. doi:10.1016/j.jhep.2017.10.031
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531:253–257.
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.
   PubMed Web of Science ®Google Scholar
• Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol. 2014;61:1376–1384.
   PubMed Web of Science ®Google Scholar
• Ganz M, Szabo G. Immune and inflammatory pathways in NASH. Hepatol Int. 2013;7:771–781.
   PubMed Web of Science ®Google Scholar
• Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66:1300–1312.
   PubMed Web of Science ®Google Scholar
• Lau J, Zhang Z, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36–44.
   PubMed Web of Science ®Google Scholar
• Hintze KJ, Benninghoff AD, Cho CE, Ward RE. Modeling the western diet for preclinical investigations. Adv Nutr. 2018;9:263–271. doi:10.1093/advances/nmy002
   PubMed Web of Science ®Google Scholar
• Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011;301:G825–834. doi:10.1152/ajpgi.00145.2011
   PubMed Web of Science ®Google Scholar
• Machado MV, Michelotti GA, Xie G, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One. 2015;10:e0127991. doi:10.1371/journal.pone.0127991
   PubMed Web of Science ®Google Scholar
• Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28:159–165. doi:10.1097/MOG.0b013e32834e7b4b
   PubMed Web of Science ®Google Scholar
• Hensley K, Kotake Y, Sang H, et al. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis. 2000;21:983–989. doi:10.1093/carcin/21.5.983
   PubMed Web of Science ®Google Scholar
• Kammoun HL, Allen TL, Henstridge DC, et al. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. PLoS One. 2017;12:e0179099. doi:10.1371/journal.pone.0179099
   PubMed Web of Science ®Google Scholar
• Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549–564. doi:10.1016/j.ccell.2014.09.003
   PubMed Web of Science ®Google Scholar
• Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987–995. doi:10.1152/ajpgi.90272.2008
   PubMed Web of Science ®Google Scholar
• Harris SE, Poolman TM, Arvaniti A, Cox RD, Gathercole LL, Tomlinson JW. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2020;319:G345–60. doi:10.1152/ajpgi.00055.2020
   PubMed Web of Science ®Google Scholar
• Dowman JK, Hopkins LJ, Reynolds GM, et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550–1561. doi:10.1016/j.ajpath.2014.01.034
   PubMed Web of Science ®Google Scholar
• Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–152. doi:10.1007/s00795-013-0016-1
   PubMed Web of Science ®Google Scholar
• Park EJ, Lee JH, Yu G-Y, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208. doi:10.1016/j.cell.2009.12.052
   PubMed Web of Science ®Google Scholar
• Chheda TK, Shivakumar P, Sadasivan SK, et al. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol. 2014;14:89. doi:10.1186/1471-230X-14-89
   PubMed Web of Science ®Google Scholar
• Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metab. 2019;29:18–26. doi:10.1016/j.cmet.2018.10.012
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Gnudi F, Vasuri F, et al. Aflatoxin B1 DNA-adducts in hepatocellular carcinoma from a low exposure area. Nutrients. 2022;14:1652. doi:10.3390/nu14081652
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476–1484. doi:10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94:93–103. doi:10.1111/iep.12008
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Kakizaki S, Takizawa D, et al. Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2008;23:276–282. doi:10.1111/j.1440-1746.2007.05150.x
   PubMed Web of Science ®Google Scholar
• Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403–414. doi:10.1016/j.cell.2008.04.013
   PubMed Web of Science ®Google Scholar
• Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774–1783. doi:10.1172/JCI20513
   PubMed Web of Science ®Google Scholar
• He L, Gubbins J, Peng Z, et al. Activation of hepatic stellate cell in Pten null liver injury model. Fibrogenesis Tissue Repair. 2016;9:8. doi:10.1186/s13069-016-0045-1
   PubMedGoogle Scholar
• Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1–28.
   PubMed Web of Science ®Google Scholar
• García-Ruiz C, Fernández-Checa JC. Mitochondrial oxidative stress and antioxidants balance in fatty liver disease. Hepatol Commun. 2018;2:1425–1439.
   PubMed Web of Science ®Google Scholar
• Bankoglu EE, Tschopp O, Schmitt J, et al. Role of PTEN in oxidative stress and DNA damage in the liver of whole-body PTEN haplodeficient mice. PLoS One. 2016;11:e0166956.
   PubMed Web of Science ®Google Scholar
• Ishii H, Horie Y, Ohshima S, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific PTEN-deficient mice. J Hepatol. 2009;50:562–571.
   PubMed Web of Science ®Google Scholar
• Chen W-T, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene. 2014;33:4997–5005.
   PubMed Web of Science ®Google Scholar
• Kawamura S, Matsushita Y, Kurosaki S, et al. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. J Clin Invest. 2022;132:e151895.
   PubMed Web of Science ®Google Scholar
• Miura K, Ishioka M, Minami S, et al. Toll-like receptor 4 on macrophage promotes the development of steatohepatitis-related hepatocellular carcinoma in mice. J Biol Chem. 2016;291:11504–11517.
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Hepatic cancer stem cells: molecular mechanisms, therapeutic implications, and circulating biomarkers. Cancers. 2021;13:4550.
   PubMed Web of Science ®Google Scholar
• Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020;122:1732–1743.
   PubMed Web of Science ®Google Scholar
• Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA. 2001;98:15089–15094.
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–197.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1654–1664.
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84:886–891.
   PubMed Web of Science ®Google Scholar
• Athavale D, Chouhan S, Pandey V, Mayengbam SS, Singh S, Bhat MK. Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9). Cancer Metab. 2018;6:16.
   PubMed Web of Science ®Google Scholar
• Lebeau PF, Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 2019;1:418–429.
   PubMedGoogle Scholar
• Zhang S-Z, Zhu X-D, Feng L-H, et al. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma. Exp Hematol Oncol. 2021;10:25.
   PubMed Web of Science ®Google Scholar
• He M, Hu J, Fang T, et al. Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway. Cancer Biol Med. 2021;19:90–103.
   PubMed Web of Science ®Google Scholar
• Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693–698.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Lee SP, Linsley PS, et al. Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: role of cholesterol. Hepatol Commun. 2022;6:780–794.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou Y, Xu H, et al. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology. 2022;76:951–966.
   PubMed Web of Science ®Google Scholar
• Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60:855–865.
   PubMed Web of Science ®Google Scholar
• Hu J, Che L, Li L, et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep. 2016;6:20484.
   PubMed Web of Science ®Google Scholar
• Che L, Chi W, Qiao Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69:177–186.
   PubMed Web of Science ®Google Scholar
• Loomba R, Mohseni R, Lucas KJ, et al. TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;161:1475–1486.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–172.
   PubMed Web of Science ®Google Scholar
• Hu B, Li H, Guo W, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2020;146:1606–1617.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shuen TWH, Toh TB, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018;67:1845–1854.
   PubMed Web of Science ®Google Scholar
• Finkin S, Yuan D, Stein I, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235–1244.
   PubMed Web of Science ®Google Scholar
• Bresnahan E, Lindblad KE. Mouse models of oncoimmunology in hepatocellular carcinoma. Clin Cancer Res. 2020;26:5276–5286.
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol. 2018;15:536–554.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2016;2:16018.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116–2126.
   PubMed Web of Science ®Google Scholar
• Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124–1141.
   PubMed Web of Science ®Google Scholar
• Chiu DK-C, Yuen VW-H, Cheu JW-S, et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology. 2020;159:609–623.
   PubMed Web of Science ®Google Scholar
• Tan S, Xu Y, Wang Z, et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling. Cancer Res. 2020;80:1130–1142.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–2970.
   PubMed Web of Science ®Google Scholar
• Torrens L, Montironi C, Puigvehí M, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;74:2652–2669.
   PubMed Web of Science ®Google Scholar
• Leslie J, Mackey JBG, Jamieson T, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022;2022:326259.
   Google Scholar
• Xue R, Zhang Q, Cao Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;2022:1.
   Google Scholar
• Shalapour S, Lin X-J, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551:340–345.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Umemura A, Taniguchi K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014;26:331–343.
   PubMed Web of Science ®Google Scholar
• Chen H-P, Shieh -J-J, Chang -C-C, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606–615.
   PubMed Web of Science ®Google Scholar
• Zhou -Y-Y, Zhu G-Q, Liu T, et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep. 2016;6:33743.
   PubMed Web of Science ®Google Scholar
• Cunha V, Cotrim HP, Rocha R, Carvalho K, Lins-Kusterer L. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review. Ann Hepatol. 2020;19:232–237.
   PubMed Web of Science ®Google Scholar
• Hsieh S-C, Tsai J-P, Yang S-F, Tang M-J, Hsieh Y-H. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids. 2014;46:2809–2822.
   PubMed Web of Science ®Google Scholar
• Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol. 2010;160:1195–1211.
   PubMed Web of Science ®Google Scholar
• Hu L, Zeng Z, Xia Q, et al. Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1α/PFKFB3/PFK1 pathway. Life Sci. 2019;239:116966.
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2014;45:322–332.
   PubMed Web of Science ®Google Scholar
• Tsai -H-H, Lai H-Y, Chen Y-C, et al. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget. 2017;8:13832–13845.
   PubMedGoogle Scholar
• Jung WJ, Jang S, Choi WJ, et al. Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. Sci Rep. 2022;12:14482.
   PubMed Web of Science ®Google Scholar
• Siddharth S, Kuppusamy P, Wu Q, Nagalingam A, Saxena NK, Sharma D. Metformin enhances the anti-cancer efficacy of sorafenib via suppressing MAPK/ERK/Stat3 axis in hepatocellular carcinoma. Int J Mol Sci. 2022;23:8083.
   PubMed Web of Science ®Google Scholar
• Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77:748–760.
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143–156.
   PubMed Web of Science ®Google Scholar
• Böhme J, Martinez N, Li S, et al. Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits. Nat Commun. 2020;11:5225.
   PubMed Web of Science ®Google Scholar
• Cho K, Ro SW, Lee HW, et al. YAP/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation. Hepatol Baltim Md. 2021;74:2605–2621.
   PubMed Web of Science ®Google Scholar